2.91
+0.04(+1.39%)
Currency In USD
| Previous Close | 2.87 |
| Open | 3.34 |
| Day High | 3.34 |
| Day Low | 2.9 |
| 52-Week High | 6.9 |
| 52-Week Low | 1.69 |
| Volume | 829,921 |
| Average Volume | 108,211 |
| Market Cap | 7.52M |
| PE | -0.76 |
| EPS | -3.81 |
| Moving Average 50 Days | 2.31 |
| Moving Average 200 Days | 2.89 |
| Change | 0.04 |
If you invested $1000 in Creative Medical Technology Holdings, Inc. (CELZ) since IPO date, it would be worth $0.35 as of July 12, 2025 at a share price of $2.91. Whereas If you bought $1000 worth of Creative Medical Technology Holdings, Inc. (CELZ) shares 5 years ago, it would be worth $126.52 as of July 12, 2025 at a share price of $2.91.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling
GlobeNewswire Inc.
Yesterday at 12:01 PM GMT
PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has re
Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain
GlobeNewswire Inc.
Mar 20, 2025 11:50 AM GMT
Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 StudyPHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (the “Company”), a clinical-stage biotechnology company s
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds
GlobeNewswire Inc.
Mar 06, 2025 1:10 PM GMT
PHOENIX, March 06, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a leading biotechnology innovator in regenerative medicine, today announced it has entered into agreements with certain holders